CITF Research Results

CITF Research Results2022-09-28T09:22:35-04:00

Derivation and validation of a clinical score to risk-stratify COVID-19 patients discharged from the emergency department

A CITF-funded study published in JACEP Open, showed that the Canadian COVID-19 Emergency Department Rapid Response Network (CCEDRRN) COVID discharge score can identify patients at risk of hospital admission or death within 72 hours of emergency department discharge. This study was led by Dr. Corinne Hohl (University of British Columbia).

January 17, 2023|General vaccine surveillance|

COVID-19 vaccine immunogenicity in people with HIV

A CITF-funded study, published in AIDS and led by Drs. Cecilia Costiniuk (McGill University) and Aslam Anis (University of British Columbia, found that vaccine-induced antibodies to SARS-CoV-2 were elicited in over 90% of people living with HIV (PLWS). Of those, most (92%), maintained those antibodies for six months following a second dose, although this percentage is less than it was for HIV-negative controls.

January 17, 2023|Higher risk due to health condition|

Striking differences in SARS-CoV-2 seroprevalence across Canada by social determinants of health

In a paper published in Microbiology Spectrum, CITF-funded researchers, including at Canadian Blood Services, showed that infection-acquired immunity to SARS-CoV-2 varied, in 2021, by age, region, racial group, the neighbourhoods in which people lived and whether they were materially or socially deprived (had fewer contacts). Interestingly, these factors were not consistent throughout all provinces and regions.

January 17, 2023|General population studies|

Kidney transplant recipients do not produce as robust an antibody response to COVID-19 vaccines as otherwise healthy individuals

CITF-funded research from Drs. Matthew Oliver and Michelle Hladunewich (University of Toronto), now published in Transplantation Direct, found that over 50% of kidney transplant recipients (KTRs) lacked Omicron-specific neutralizing antibodies one month following a third vaccine dose. Antibody levels in those that developed the Omicron-specific antibodies were well preserved at 3 months.

January 9, 2023|Higher risk due to health condition|

Vaccine-induced immune responses are as durable in people living with HIV as in people without HIV

A CITF-funded study published in AIDS, from Mark Brockman and Zabrina Brumme (Simon Fraser University and BC Centre for Excellence in HIV/AIDS), along with Drs. Aslam Anis and Marc Romney (University of British Columbia) showed that the antibody responses induced by a third dose of COVID-19 vaccine were as durable in people living with HIV (PLWH) receiving antiretroviral therapy (ART) as in individuals without HIV.

January 9, 2023|Higher risk due to health condition|
Go to Top